Anuh Pharma Ltd. (BSE: 506260) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹832 Cr, it ranks #1,687 by market cap among the 6,137 Indian listed companies on FinBizNet, and #51 of 86 in Medicinal Chemicals and Botanical Products. At ₹76.63 (as of 25 Oct 2026), the share price is 23.0% below its 52-week high of ₹99.50 and 14.4% above its 52-week low of ₹67.00. The share price is down 3.9% over one year and down 3.1% over three months.
| Current Price | ₹76.63 |
|---|---|
| Market Cap | ₹832 Cr |
| BSE Code | 506260 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 20.3 |
| Return on Equity | 12.10% |
| Return on Assets | 6.63% |
| 52-Week Range | ₹67.00 – ₹99.50 |
| 1-Year Price Change | -3.9% |
| 3-Month Price Change | -3.1% |
| Beta (1Y) | 0.3 |
| Dividend Yield | 1.81% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.anuhpharma.com |
| Revenue | ₹194 Cr |
|---|---|
| Net Profit | ₹11 Cr |
| Net Margin | 5.9% |
| EPS (Basic) | ₹1.14 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Anuh Pharma Limited engages in the manufacture and sale of bulk drugs and chemicals in India. It offers active pharmaceutical ingredients, including macrolides, anti-TB, anti-bacterial, anti-asthmatics, anti-diabetics, intermediates, expectorant, quinolones, anti-malarial, anti-gout, anti-biotic, anti-platelet, and antihistamines; and corticosteroids, including anti-inflammatory, immunosuppressant, anti-pruritic, anti-mitotic. The company also develops products, such as coagulants, gastrointestinal, anti convulsants, and cholesterol drugs. It also exports its products. The company was incorporated in 1960 and is headquartered in Mumbai, India.
1. Bulk Drug and Chemicals-This segment manufactures and sells bulk drugs and chemicals.
1. Bulk Drug and Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Anuh Pharma Ltd. | ₹832 Cr | 20.3 | 12.10% | ₹194 Cr | -3.9% |
Listed by market capitalisation. Ratios are shown for context only.
Anuh Pharma Ltd. is trading at ₹76.63, with a market capitalisation of ₹832 Cr.
Anuh Pharma Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Anuh Pharma Ltd. has a P/E of 20.3 and a return on equity of 12.10%.
Anuh Pharma Ltd. is listed on the BSE under the scrip code 506260.
Anuh Pharma Ltd.'s share price is down 3.9% over one year and down 3.1% over three months. Its 52-week range is ₹67.00 to ₹99.50.
In Q1 FY27, Anuh Pharma Ltd. reported revenue of ₹194 Cr and net profit of ₹11 Cr, with basic EPS of ₹1.14 (standalone, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.